Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ALN-BCAT |
| Trade Name | |
| Synonyms | ALNBCAT|ALNBCAT |
| Drug Descriptions |
ALN-BCAT comprises siRNA targeted against beta-catenin (CTNNB1) in a lipid nanoparticle formulation, which potentially increases antitumor immune response and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 5924). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ALN-BCAT | ALN-BCAT | 0 | 1 |
| ALN-BCAT + Pembrolizumab | ALN-BCAT Pembrolizumab | 0 | 1 |